Investor Relations

Investor Relations

Recent Event

Biotech Showcase 2020

Latest Financial Results

Q3 2019

Quarter Ended Sep 30, 2019

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2018

Company Overview

Emerald Bioscience is a biopharmaceutical company headquartered in Long Beach, California, focused on the discovery, development, and commercialization of bioengineered cannabinoid-based therapeutics for significant unmet medical needs in global markets. With proprietary technology licensed from the University of Mississippi, Emerald is developing novel ways to deliver cannabinoid-based drugs for specific indications with the aim of optimizing the clinical effects of such drugs while limiting potential adverse events. Emerald's strategy is to clinically develop a number of proprietary biosynthetic compounds, alone or in combination with corporate partners.

Investor Contact Information


Emerald Bioscience, Inc.
130 North Marina Drive
Long Beach, CA 90803

Investor Relations

PCG Advisory Group
Adam Holdsworth
T: 646-862-4607

Transfer Agent

ClearTrust, LLC
16540 Pointe Village Dr.
Suite 210
Lutz, FL 33558
T: 813-235-4490